Anticoagulation in End-Stage Renal Disease

Introduction to Anticoagulation Options

The American College of Cardiology recommends that DOACs should generally be avoided in patients with end-stage renal disease (ESRD, CrCl <15 mL/min) or on dialysis, with the notable exception of apixaban, which is FDA-approved in the United States for chronic, stable hemodialysis patients at 5 mg twice daily, though 2.5 mg twice daily may provide more appropriate drug levels 1, 2

European regulatory authorities (EMA) contraindicate all DOACs in patients with CrCl <15 mL/min or on dialysis, while the FDA permits more liberal use, particularly for apixaban 1, 4
The evidence base for DOAC use in ESRD remains weak, as patients on dialysis were systematically excluded from landmark DOAC trials, and current recommendations are based primarily on pharmacokinetic data rather than hard clinical endpoint studies demonstrating mortality or morbidity benefits 3, 4

Apixaban has the lowest renal clearance (27%) among all DOACs, making it theoretically the safest option in severe renal impairment, and the FDA-approved dose is 5 mg twice daily for chronic, stable hemodialysis patients, though 2.5 mg twice daily may provide more appropriate drug levels 1, 2
Dabigatran is contraindicated in ESRD due to 80% renal elimination, and the EMA contraindicates it for CrCl <30 mL/min, while the FDA permits 75 mg twice daily in severe CKD (CrCl 15-30 mL/min) but not for dialysis 1, 3, 4
Rivaroxaban and edoxaban are not recommended for use in ESRD due to limited clinical data and high renal clearance, which poses a significant accumulation risk 3, 4, 5

Well-managed warfarin with time in therapeutic range (TTR) >65-70% remains a reasonable alternative for ESRD patients requiring anticoagulation, although it carries specific risks in this population, including increased bleeding risk, risk of calciphylaxis, and enhanced vascular calcification 1, 2, 4

For ESRD patients requiring anticoagulation, the first-line option is well-managed warfarin (TTR >65-70%) with close INR monitoring, and apixaban 2.5 mg twice daily is an alternative in the US only for patients on chronic, stable hemodialysis 1, 2
All other DOACs (dabigatran, rivaroxaban, edoxaban) should be avoided in dialysis-dependent ESRD 1, 3, 4

Renal function assessment is required before initiating any DOAC, and patients with CrCl <60 mL/min should have their renal function monitored at a minimum frequency (in months) = CrCl/10, with increased monitoring during acute illness and patient education to contact providers during acute illnesses 5